Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity.
Deleobuvir demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays.
Deleobuvir shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ.
Deleobuvir displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients.
